Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy

Cancer Research

Volumn 65, Issue 22, 2005, Pages 10145-10148

  Hay, Trevor ^a   Jenkins, Helen ^b   Sansom, Owen J ^a,c   Martin, Niall M B ^b   Smith, Graeme C M ^b   Clarke, Alan R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b KuDOS Pharmaceuticals Ltd   (United Kingdom)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; KU 0058948; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; GENE DELETION; HETEROZYGOTE; INJECTION; INTESTINE EPITHELIUM; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SMALL INTESTINE;

ANIMALS; APOPTOSIS; BIOLOGICAL AVAILABILITY; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA DAMAGE; ENZYME INHIBITORS; FLUOROBENZENES; GENE DELETION; GENES, BRCA2; INTESTINAL MUCOSA; INTESTINE, SMALL; MICE; MICE, TRANSGENIC; PHTHALAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 28544433970     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1186     Document Type: Article

References (20)

1. Pellegrini L, Venkitaraman A. Emerging functions of BRCA2 in DNA recombination. Trends Biochem Sci 2004;29:310-6.
2. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003;22:5784-91.
3. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386:804-10.
4. Donoho G, Brenneman MA, Cui TX, et al. Deletion of Brca2 exon 27 causes hypersensitivity to DNA cross-links, chromosomal instability, and reduced life span in mice. Genes Chromosomes Cancer 2003;36:317-31.
5. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34.
6. Chen P-L, Chen C-F, Chen Y, Xiao J, Sharp ZD, Lee W-H. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 1998;95:5287-92.
7. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998;90:978-85.
8. Patel KJ, Yu VPCC, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell 1998;1:347-57.
9. Morimatsu M, Donoho G, Hasty P. Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to γ-radiation and premature senescence. Cancer Res 1998;58:3441-7.
10. Kraakman-van der Zwet M, Overkamp WJI, van Lange REE, et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol 2002;22:669-79.
11. Hay T, Patrick T, Winton D, Sansom OJ, Clarke AR. Brca2 deficiency in the murine small intestine sensitizes to p53-dependent apoptosis and leads to the spontaneous deletion of stem cells. Oncogene 2005;24:3842-6.
12. Bryant HE, Helleday T. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochem Soc Trans 2004;32:959-61.
13. Bouchard VJ, Rouleau M, Poirier GG. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 2003;31:446-54.
14. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
15. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
16. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371-82.
17. Calabrese CR, Almassy R, Barton S. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
18. Ireland H, Kemp R, Houghton C, et al. Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of β-catenin. Gasteroenterology 2004;126:1236-46.
19. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004;18:1385-90.
20. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999;21:70-1.